Stockscreener 앱 받기
8.98
4.91%
0.42
시간 외 거래:
8.99
0.010
+0.11%
전일 마감가:
$8.56
열려 있는:
$9.94
하루 거래량:
727.99K
Relative Volume:
0.84
시가총액:
$458.05M
수익:
$120.00K
순이익/손실:
$-209.18M
주가수익비율:
-2.2815
EPS:
-3.936
순현금흐름:
$-185.05M
1주 성능:
+6.27%
1개월 성능:
-2.07%
6개월 성능:
+36.06%
1년 성능:
+136.94%
1일 변동 폭
$8.56
$9.94
1주일 범위
$8.21
$9.94
52주 변동 폭
$2.235
$12.34
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
8.98 | 436.63M | 120.00K | -209.18M | -185.05M | -3.936 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-11-07 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st
4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Target to $35 | FDMT Stock News - GuruFocus
RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics (FDMT) Reports 2025 Financial Results, Advances 4D-150 Wet AMD Phase 3 Trials, and Extends Cash Runway Into 2028 - Minichart
4D Molecular Therapeutics, Inc. 2025 Annual Report: Innovative AAV Gene Therapy Pipeline for Retinal and Pulmonary Diseases - Minichart
4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue - Bitget
4D Molecular Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
4D Molecular Therapeutics : 4DMT Corporate Presentation – March 2026 (dfceb5) - marketscreener.com
4D Molecular Therapeutics 10-K: $85.2M collaboration revenue; improved net loss $140.1M - TradingView
4D Molecular Therapeutics (FDMT) details retina and lung gene therapy pipeline in 10-K - Stock Titan
4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway - Stock Titan
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire
Biotech 4D Molecular Therapeutics lines up March investor conference talks - Stock Titan
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference - Yahoo Finance
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk - Yahoo Finance
FDMT: 4D-150's rapid phase III progress and broad commercialization plans highlight strong market potential - TradingView
FDMT: Rapid phase 3 progress and strong market interest position 4D-150 for global commercialization - TradingView
FDMT: 4D-150 shows strong efficacy and safety, with global phase III trials advancing ahead of schedule - TradingView
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
FDMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? - Finviz
FDMT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Chardan Capital maintains 4D Molecular Therapeutics (FDMT) buy recommendation - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%Time to Buy? - MarketBeat
Key Catalysts on the Horizon for 4D Molecular Therapeutics - AD HOC NEWS
4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Friday - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
Biotech 4DMT heads to three March healthcare investor conferences - Stock Titan
Novo Holdings A/S reports 6.4% passive stake in 4D MT (FDMT) - Stock Titan
4DMT Announces New Employment Inducement Grants - The Manila Times
Biotech 4DMT hands 124,200 stock units to just nine recruits - Stock Titan
4D Molecular Therapeutics Advances Toward Phase 3 Milestones in Retina Gene Therapy - AD HOC NEWS
Barclays flags M&A tailwinds and pricing relief as upside catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - MSN
Will 4D Molecular Therapeutics Inc. stock attract ESG investorsJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - mfd.ru
Will 4D Molecular Therapeutics Inc. benefit from geopolitical trends2025 Institutional Moves & Smart Allocation Stock Reports - mfd.ru
What are analysts’ price targets for 4D Molecular Therapeutics Inc.2025 Support & Resistance & Entry Point Strategy Guides - mfd.ru
4D Molecular (FDMT) Completes Enrollment for Key Phase 3 Wet AMD Trial - GuruFocus
What is 4D Molecular Therapeutics Inc. s debt to equity ratioEarnings Recap Summary & Reliable Price Breakout Alerts - mfd.ru
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD - Yahoo Finance
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Finviz
Barclays Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Overweight Recommendation - Nasdaq
Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
4D Molecular Therapeutics Restructures Equity via Warrant Exchange - TipRanks
4D Molecular Therapeutics: A Valuation Disconnect Amidst Clinical Progress - AD HOC NEWS
4D Molecular (FDMT) Grants RSUs to New Employees - GuruFocus
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees - Intellectia AI
Biotech 4DMT hands 23,600 stock units to four new hires under award plan - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update - MarketBeat
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial potential in retinal disease - TradingView
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):